Skip to content
Medical Health Aged Care

Better, faster medical intervention for people suffering heart attacks and angina

Heart Foundation 4 mins read

Heart Foundation and Cardiac Society of Australia and New Zealand launch updated heart attack treatment advice

People suffering heart attacks and angina in Australia will now be diagnosed and treated faster and more effectively thanks to a new clinical guideline for Acute Coronary Syndromes (ACS) released today.

The launch of the new Guideline comes as the Heart Foundation reminds people not to delay calling Triple Zero if they experience symptoms.

The updated acute coronary syndromes (ACS) Guideline provides doctors and emergency department healthcare workers with the most up to date tools and recommendations to diagnose potential heart attacks and angina.

One of the key updates is the inclusion of a new treatment pathway which involves using a more sensitive blood test to help doctors in emergency departments more rapidly determine if chest pain is a heart attack or not.

Rapid, accurate identification of heart attack

Troponin is a protein that is released into the blood when heart cells are damaged.

Heart Foundation Chief Medical Adviser, Professor Garry Jennings said the new treatment pathway more strongly recommends a high-sensitivity cardiac troponin blood test which would allow healthcare professionals to more quickly and accurately detect heart attacks when people presented for care.

People encouraged to act quickly on heart attack symptoms

The Heart Foundation is leveraging the launch of the new Guideline to remind people to be aware of heart attack symptoms and call Triple Zero (000) immediately – even if unsure.

“Every minute matters with a heart attack,” Professor Jennings said.

 

“We still have delays in people presenting for evaluation of heart attack in Australia and that’s something not for the clinicians, but for patients to consider the warning signs and act on them without delay.”

Melissa’s story

New South Wales resident Melissa Gardiner was 52 years old in October 2021 when she was shocked to learn she had experienced a heart attack.  With shortness of breath and arm pain as her only identifiable symptoms, Melissa is now aware of the range of heart attack symptoms, such as fatigue, nausea, vomiting and dizziness.

 

“When I had my heart attack, I didn’t know it was a heart attack. I think when people think of a heart attack, they think of a person clutching their chest and dropping to the ground, but not everyone experiences one like that,” she said.

 

“If the guideline is going to help people get recognised for a heart attack quicker, it is going to save lives. I’m sure plenty of people have symptoms of a heart attack, but they aren’t picked up straight away.”

In addition to the initial diagnosis and treatment of heart attack, the new guideline includes recommendations to support a person’s recovery and reduce their risk of a repeat event.

These recommendations underpin the Heart Foundation’s MyHeart MyLife patient support program, designed to help people who have had a heart attack or been diagnosed with coronary heart disease to reduce the risk of another event and improve their quality of life.

Key updates in the new guideline

  • New treatment pathway using high-sensitivity cardiac troponin blood tests for faster and more accurate diagnosis of heart attacks
  • Stronger recommendations on the timing of heart attack treatment to improve a person’s chance of survival and quality of life
  • New advice on blood thinning medicines used to prevent repeat heart attacks in the long term
  • New treatment target for cholesterol
  • How to manage specific types of heart attack and serious complications, including new advice on the management of SCAD, a condition more commonly experienced by women
  • Practice points which address the unique needs of priority populations with suspected or confirmed ACS including women, older adults, First Nation peoples and people living in regional and remote areas
  • Best practice care after discharge from hospital, including mental health support for better health and quality of life after a heart attack.

 

Detecting under-recognised heart attacks

Professor Jennings highlighted the recognition of heart attack variations as a key inclusion in the new guideline.

“In the past, heart attacks were largely understood as resulting from a narrowed and blocked artery, but we now know there are variations to this and the need for different treatments,” Prof Jennings said.

“One example would be spontaneous coronary artery dissection (SCAD), a condition that primarily affects women and requires a different approach to management. As our understanding of SCAD and its underlying cause has improved, treatment has become more tailored, and this is recognised in the new guideline which now encourages healthcare professionals to consider SCAD as a potential cause of ACS.”

Tailored practice advice for underserved populations

The guideline includes practice points which address the unique needs of priority populations with suspected or confirmed ACS.

“We know that disparities still exist in the diagnosis and treatment of heart attack in some groups of people,” explained Prof Jennings.

“These groups include women, older adults, First Nations peoples and people living in regional and remote areas. Including practice advice tailored to these groups in the guideline is a critical step to reducing inequities in the care of people with ACS.”

How the guideline was developed

The guideline has been developed by the National Heart Foundation of Australia (Heart Foundation) in collaboration with the Cardiac Society of Australia and New Zealand. The Heart Foundation acknowledges partial funding from the Cardiac Society of Australia and New Zealand and Perpetual towards the development of the guideline.

The new guideline replaces the National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016

It has been endorsed by 15 peak body organisations to date including:

  • Advanced Pharmacy Australia (AdPha)
  • Australasian Cardiovascular Nursing College (ACNC)
  • Australasian College for Emergency Medicine (ACEM)
  • Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS)
  • Australian Cardiovascular Health and Rehabilitation Association (ACRA)
  • Australian Physiotherapy Association (APA)
  • Central Australian Rural Practitioners Association (CARPA)
  • Council of Remote Area Nurses of Australia (CRANA)
  • Exercise & Sports Science Australia (ESSA)
  • Internal Medicine Society of Australia and New Zealand (IMSANZ)
  • National Association of Aboriginal and Torres Strait Islander Health Workers and Practitioners (NAATSIHWP)
  • The Australasian College of Paramedicine (ACP)
  • The Australian Resuscitation Council (ARC)
  • The National Rural Health Alliance (NRHA)
  • The Royal College of Pathologists of Australasia (RCPA).

About us:

About the Heart Foundation

The Heart Foundation is a not-for-profit organisation dedicated to fighting the single biggest killer of Australians – heart disease. For more than 60 years, it has led the battle to save lives and improve the heart health of all Australians. Its sights are set on a world where people don’t suffer or die prematurely because of heart disease.

Find out your risk of heart attack or stroke by using our Heart Age Calculator. To find out about the Heart Foundation’s research program or to make a donation, visit www.heartfoundation.org.au


Contact details:

Erin Marie, Senior Media Advisor, Heart Foundation

M: 0439 366 992

E: [email protected]

More from this category

  • Medical Health Aged Care
  • 25/04/2025
  • 18:11
Elixir Medical Corporation

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea.Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an external energy source.MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in the Asia Pacific region, marking a significant milestone in the device's global introduction. The procedures were successfully performed…

  • Medical Health Aged Care
  • 25/04/2025
  • 09:59
Monash University

Repurposed diabetes drug can reduce pain for those with knee arthritis and overweight or obesity: study

A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements, Monash University-led research has found. Metformin, which is commonly prescribed to treat type 2 diabetes, reduced knee arthritis pain over six months in a clinical trial published in JAMA. The randomised clinical trial looked at whether metformin, compared to a placebo, reduced knee pain in patients withsymptomatic knee osteoarthritis (knee OA) andoverweight or obesity. The research was performed entirely as a community-based study using telehealth. Some of the 107 participants with pain from knee osteoarthritis (73…

  • Medical Health Aged Care
  • 24/04/2025
  • 21:41
UPS

UPS to Acquire Andlauer Healthcare Group for $1.6 Billion, Strengthening its Global Offerings in Complex Healthcare Logistics

Acquisition will Enhance End-to-End Capabilities and Service to Healthcare Customers Needing Temperature-Controlled Logistics Solutions in North America ATLANTA–BUSINESS WIRE– UPS(NYSE: UPS) today announced that…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.